Ludwig scientists around the world are continually making discoveries that alter our understanding of cancer. Our science is featured in the most prestigious journals and in general media. Explore some of our most recent findings, news and reports.
For media inquiries, contact
Vice President for Communications
Ludwig scientists share new findings on immunotherapy, drug resistance and tumor evolution at 2016 AACR Annual Meeting
Ludwig Cancer Research released today the full scope of advances presented by Ludwig researchers at this year’s American Association for Cancer Research (AACR) Annual Meeting in New Orleans, La., April 16–20. Research conducted by more than 70 Ludwig scientists will be presented in symposiums, plenaries and poster sessions, and Ludwig researchers will participate in several workshops and meet-the-expert sessions over the course of the Meeting.
“The AACR Annual Meeting is a principle forum for Ludwig researchers to forge collaborations and discuss long-term strategies for applying our discoveries to develop new interventions for the prevention, diagnosis and treatment of cancer,” said David Lane, PhD, Scientific Director, Ludwig Institute for Cancer Research.
Ludwig scientists will share insights and new data at the Meeting on discoveries stemming from both basic and translational research. Presentations on basic research will cover areas such as cancer genomics, tumor cell diversity, intracellular signaling, the development of “liquid biopsies” and a variety of studies on tumor immunology.
Ludwig presentations on translational and clinical research will cover—among many other things—immunotherapeutic strategies for a variety of cancers, the long-term survival of melanoma patients who received anti-PD-1 therapy, the design and initial clinical evaluation of an adoptive T cell therapy against a common cancer antigen and the relationship between inflammation, obesity and tumor progression in pancreatic cancer.
Click here for a comprehensive list of Ludwig scientists’ activities at the Meeting.